



## Structured Administration and Supply Agreement

### SASA Details

Title:	Administration of clindamycin for intrapartum prophylaxis of Group B Strep (GBS)
Identifying Number:	<a href="#">ED-CO-24-239364</a>

### Issuing Authority

Hospital Name:	WACHS CEO under section 6 Medicine and Poisons Regulations 2016
Address:	189 Wellington Street, PERTH 6000
Contact:	9223 8525

### Authorised Persons

Practitioners:	Midwives
Location:	WACHS Maternity units, Midwifery Group Practice and home birth programs
Qualification:	APHRA registered Midwives

### Authorised Medicine

Medicine Name:	Clindamycin	Brand:	
Form:	Injection	Strength:	600 mg (4ml ampoule)
Dose:	600 mg	Quantity:	Continue 8 hourly until baby is born
Route:	Intravenous injection		
Instructions:	<a href="#">KEMH Clinical Practice Guidelines – Group B Streptococcal Disease</a> <a href="#">KEMH Obstetrics and Gynaecology Medication Guidelines – Clindamycin</a>		

### Approved Circumstances

Authorised to:	Midwives employed by WACHS Maternity units.
Place:	WACHS hospitals with maternity or obstetric services
Patients:	Consenting intrapartum women her GBS status unknown or positive, history of previous infant with early onset GBS disease or maternal GBS bacteriuria this pregnancy and allergic to Penicillin <a href="#">WACHS Prevention of Maternal and Newborn Sepsis Policy (health.wa.gov.au)</a>
Medical Condition:	Intrapartum Prophylactic Antibiotics for GBS

Clindamycin for Group B Streptococcal Disease

<b>Clinical / Other Information</b>	
Patient Inclusion	<a href="#">KEMH Clinical Practice Guidelines – Group B Streptococcal Disease</a> <a href="#">WACHS Prevention of Maternal and Newborn Sepsis Policy (health.wa.gov.au)</a>
Patient Exclusion:	<a href="#">KEMH Clinical Practice Guidelines – Group B Streptococcal Disease</a> <a href="#">KEMH Obstetrics and Gynaecology Medication Guidelines – Clindamycin</a> <a href="#">WACHS Prevention of Maternal and Newborn Sepsis Policy (health.wa.gov.au)</a>
Special Instructions:	<a href="#">KEMH Clinical Practice Guidelines – Group B Streptococcal Disease</a> <a href="#">KEMH Obstetrics and Gynaecology Medication Guidelines – Clindamycin</a>
Administration Notes:	Administer as per relevant KEMH clinical guidelines
Clinical Guidelines	<a href="#">WACHS Prevention of Maternal and Newborn Sepsis Policy (health.wa.gov.au)</a> <a href="#">KEMH Clinical Practice Guidelines – Group B Streptococcal Disease</a> <a href="#">KEMH Obstetrics and Gynaecology Medication Guidelines – Clindamycin</a>

<b>Approval</b>			
Date of Issue:	31/07/2024		
Date of Expiry:	30/07/2026		
Clinical Governance Committee			
Committee:	Medicines and Therapeutics Committee		
Chair:	Dr Helen Van Gessel		
Date:	26 June 2024	Signature:	Helen Van Gessel
Nurse	Kate Reynolds, Coordinator of Midwifery		
Date	01 July 2024	Signature:	Kate Reynolds
Senior Medical Practitioner			
Name:	Dr Helen van Gessel		
Date:	26 June 2024	Signature:	Helen Van Gessel
Chief Executive			
Name:	Mr Jeff Moffet		
Date:	31 July 2024	Signature:	Jeff Moffet